Predicting Scoliosis Progression From 3D Imaging, Study Shows Promising Results
EOS imaging (NYSE Euronext, FR0011191766 - EOSI), the pioneer in 2D/3D orthopedic medical imaging, announces today results of a new clinical study highlighting the value of 3D spine measurements provided by the EOS® imaging system for monitoring and predicting scoliosis progression as of the patient's first medical visit. The data was presented at the 47th annual conference of the Scoliosis Research Society (SRS).
Dr. Stefan Parent, of Sainte-Justine Hospital in Montreal and lead investigator, says, "This study sheds new light on the benefits of the EOS 3D technology in more precisely assessing and predicting the progression of scoliosis. The 3D parameters measured using EOS improve our ability to choose the most appropriate treatment path for our adolescent patients, whether it be monitoring, use of a brace or surgery. This is a considerable benefit for the surgeon and especially for the patient."
The prospective study, financed by the Canadian Institutes of Health Research and the FRSQ (Fonds de recherche en Santé du Québec, the Quebec Health Research Fund), involved 134 patients with Adolescent Idiopathic Scoliosis (AIS). The findings demonstrated that the 3D morphological parameters of the spine obtained with EOS® can be used to distinguish between progressive scoliosis and non-progressive scoliosis from the point of the first medical visit. Such a distinction is not possible on the basis of two-dimensional parameters. The propensity of scoliosis to develop and worsen, or not, is a major challenge when choosing therapies, which are costly and invasive.
Marie Meynadier, CEO of EOS imaging, says, "Scoliosis, which has long been detected and monitored in 2D, can now benefit from these very significant results, which might improve the care pathway, benefiting both patients and healthcare systems. This study, which was presented during a major conference for the profession, strengthens the visibility of EOS among orthopaedic professionals and its clinical value to improve care for their patients."